Elacestrant
- Generic Name
- Elacestrant
- Brand Names
- Orserdu
- Drug Type
- Small Molecule
- Chemical Formula
- C30H38N2O2
- CAS Number
- 722533-56-4
- Unique Ingredient Identifier
- FM6A2627A8
- Background
Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its abili...
- Indication
Elacestrant is indicated for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath